Cardiovascular events associated with the use of four nonselective NSAIDs (Etodolac, Nabumetone, Ibuprofen, or Naproxen) Versus a Cyclooxygenase-2 Inhibitor (Celecoxib): A population-based analysis in taiwanese adults

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1827-1836

  Huang, Weng Foung ^a   Hsiao, Fei Yuan ^a   Wen, Yu Wen ^b   Tsai, Y Wen ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

adverse drug events; celecoxib; data analysis; NSAIDs

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ANAMNESIS; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; OUTCOME ASSESSMENT; POPULATION RESEARCH; REFERENCE DATABASE; RISK ASSESSMENT; RISK FACTOR; TAIWAN; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PYRAZOLES; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES; TAIWAN; TIME FACTORS;

EID: 33845946506     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.009     Document Type: Article

References (30)

1. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
2. Gajraj N.M. Cyclooxygenase-2 inhibitors. Anesth Analg. 96 (2003) 1720-1738
3. Adverse Drug Reactions Advisory Committee. Rofecoxib, celecoxib, and cardiovascular risks. Aust Adv Drug Reactions Bull 22 (2003) 19
4. Graham D.J., Campen D., Cheetham C., et al. Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective nonsteroidal anti-inflammatory drugs [abstract]. Pharmacoepidemiol Drug Saf. 13 (2004) S287-S288
5. Ray W.A., Stein C.M., Daugherty J.R., et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360 (2002) 1071-1073
6. Day R. Hypertension in the patient with arthritis: Have we been underestimating its significance?. J Rheumatol. 30 (2003) 642-645
7. Ray W.A., Griffin M.R., and Stein C.M. Cardiovascular toxicity of valdecoxib. N Engl J Med. 351 (2004) 2767
8. Farkouh M.E., Kirshner H., Harrington R.A., et al., TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 364 (2004) 675-684
9. Finckh A., and Aronson M.D. Cardiovascular risks of cyclooxygenase-2 inhibitors: Where we stand now. Ann Intern Med. 142 (2005) 212-214
10. Edwards I.R. What are the real lessons from Vioxx?. Drug Saf. 28 (2005) 651-658
11. Topol E.J. Arthritis medicines and cardiovascular events-"house of coxibs". JAMA 293 (2005) 366-368
12. Topol E.J., and Falk G.W. A coxib a day won't keep the doctor away. Lancet 364 (2004) 639-640
13. Hampton T. Experts point to lessons learned from controversy over rofecoxib safety. JAMA 293 (2005) 413-414
14. Bannwarth B. Do selective cyclo-oxygenease-2 inhibitors have a future?. Drug Saf. 28 (2005) 183-189
15. Kuehn B. FDA panel: Keep COX-2 drugs on market: Black box for COX-2 labels, caution urged for all NSAIDs. JAMA 293 (2005) 1571-1572
16. Hampton T. Officials halt NSAID prevention trials. JAMA 293 (2005) 664-665
17. Available at. US Food and Drug Administration. Analysis and recommendations for agency action-COX-2 selective and nonselective NSAIDs. Accessed (August 10, 2005). http://www.fda.gov/cder/drug/infopage/COX2/defauIt.htm
18. Solomon S.D., McMurray J.J., Pfeffer M.A., et al., Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 352 (2005) 1071-1080
19. [published correction appears in N Engl J Med. 2006;355: 221]. Bresalier R.S., Sandler R.S., Quan H., et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofe coxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 352 (2005) 1092-1102
20. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 352 (2005) 1081-1091
21. Shaya F.T., Blume S.W., Blanchette C.M., et al. Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population. Arch Intern Med. 165 (2005) 181-186
22. Kimmel S.E., Berlin J.A., and Reilly M. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 142 (2005) 157-164
23. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 365 (2005) 475-481
24. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44 (2005) 677-680
25. Harrison-Woolrych M., Herbison P., McLean R., et al. Incidence ofthrombotic cardiovascular events in pa tients taking celecoxib compared with those taking rofecoxib: Interim results from the New Zealand Intensive Medicines Monitoring Programme. Drug Saf. 28 (2005) 435-442
26. Kasliwal R., Layton D., Harris S., et al. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Drug Saf 28 (2005) 803-816
27. Huang W.F., Hsiao F.Y., Tsai Y.W., et al. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: An observational study. Drug Saf. 29 (2006) 261-272
28. US Dept of Health and Human Services. Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS). International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (2003), NCHS, Hyattsville, Md
29. Topol E.J. Failing the public healthrofecoxib, Merck, and the FDA. N Engl J Med. 351 (2004) 1707-1709
30. Drazen J.M. COX-2 inhibitors-a lesson in unexpected problems. N Engl J Med. 352 (2005) 1131-1132